SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (5957)10/13/1998 5:41:00 PM
From: Sonki  Read Replies (3) | Respond to of 9523
 
anthony, we have to dig it up. i know , i m not wrong. cuz analysts
were trying to increase the estimates going forward last qurter but
the company downplayed and explicitly said they were comfortable with this ---- number. specific numbers. which were the current estimates.

i can not belive PFE would do this.
i really hope i m wrong cuz i have a great deal of respect for the management.



To: Anthony Wong who wrote (5957)10/13/1998 6:19:00 PM
From: Uncle Frank  Read Replies (1) | Respond to of 9523
 
>>Sonki, I don't recall whether they had said that they were comfortable with earnings estimate...

Anthony, The comment you're looking for is contained in the earnings press release, via a quote from David L. Shedlarz, senior vice president and chief financial officer:

''In the past,'' he continued, ''we noted that we were comfortable with the range of the majority of analysts' diluted earnings-per-share estimates of $2.05 to $2.10 for the year, excluding the impacts of acquisitions, divestitures, licensing fees, legal settlements and other unusual and non- recurring items. The divestiture of the MTG businesses (with earnings expected
at about 10 cents per share on a full-year basis) now indicates a range of $1.95 to $2.00 per share for the full year from continuing operations, excluding unusual and non-recurring items, with which we remain comfortable.